Does bitemporal ECT improve outcomes in patients with NMS refractory to pharmacotherapy?
Bitemporal ECT should be considered early for neuroleptic malignant syndrome refractory to pharmacological interventions.
Bitemporal ECT was well tolerated and effective in treating NMS refractory to pharmacotherapy. We suggest that ECT be considered early in cases of NMS that are refractory to pharmacological interventions, especially if the underlying condition is also responsive to ECT.
Morcos et al. (2019) studied this question.